Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
6.–10. rezultāts no 100.
304. lappuse
... injection . [ 39 FR 11750 , Mar. 29 , 1974 , as amended at 39 FR 40286 , Nov. 15 , 1974 ] Subpart E - Certification § 429.40 Requests for certification ; samples ; storage ; approvals prelimi- nary to certification . ( a ) A request for ...
... injection . [ 39 FR 11750 , Mar. 29 , 1974 , as amended at 39 FR 40286 , Nov. 15 , 1974 ] Subpart E - Certification § 429.40 Requests for certification ; samples ; storage ; approvals prelimi- nary to certification . ( a ) A request for ...
305. lappuse
... injection , except that it may contain approximately 40 , 80 , or 100 units of insulin per milliliter in a quantity containing approximately 5,000 U.S.P. units of insulin . ( 3 ) If the batch is to be protamine zinc insulin suspension ...
... injection , except that it may contain approximately 40 , 80 , or 100 units of insulin per milliliter in a quantity containing approximately 5,000 U.S.P. units of insulin . ( 3 ) If the batch is to be protamine zinc insulin suspension ...
306. lappuse
... injection , prot- amine zinc insulin suspension , globin zinc insulin injection , or isophane insu- lin suspension are not required if the Commissioner has previously approved a trial mixture containing 40 , 100 units of insulin per ...
... injection , prot- amine zinc insulin suspension , globin zinc insulin injection , or isophane insu- lin suspension are not required if the Commissioner has previously approved a trial mixture containing 40 , 100 units of insulin per ...
308. lappuse
... injection , isophane insulin suspension , insulin zinc suspension , prompt insulin zinc suspension , or extended insulin zinc suspension ; the Commissioner shall certify that such batch is safe and efficacious for use , subject to such ...
... injection , isophane insulin suspension , insulin zinc suspension , prompt insulin zinc suspension , or extended insulin zinc suspension ; the Commissioner shall certify that such batch is safe and efficacious for use , subject to such ...
352. lappuse
... injection . 436.365 Thin layer chromatographic identity test for rifampin . 436.366 High - performance liquid chroma- tography assay for determining chromatographic purity of vancomycin . 436.367 Thin - layer chromatographic identity ...
... injection . 436.365 Thin layer chromatographic identity test for rifampin . 436.366 High - performance liquid chroma- tography assay for determining chromatographic purity of vancomycin . 436.367 Thin - layer chromatographic identity ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning